WebDoctor Encyclopedia

Lung Non-small cell lung cancer

Pulmonary blastoma (adult type)

Pulmonary blastoma is a very rare adult lung cancer that looks like embryonic lung tissue, with both gland cells and immature stroma. Most carry DICER1 and beta-catenin changes, and treatment centres on surgery, sometimes with chemotherapy and radiotherapy.

Medically reviewed Last reviewed October 20, 2026

What is pulmonary blastoma?

Pulmonary blastoma is a very rare lung cancer that mainly affects adults. Its name comes from its appearance: under the microscope, the tumour looks like the lung of an embryo in the early weeks of development. It contains two kinds of cancerous tissue mixed together: gland-forming epithelial cells and an immature, sarcoma-like supporting tissue (stroma). Because it has these two parts, it is called biphasic.

Adult pulmonary blastoma is a different disease from pleuropulmonary blastoma, a childhood lung tumour that is usually linked with an inherited DICER1 gene variant. In current classifications, adult pulmonary blastoma is grouped with the sarcomatoid carcinomas, a family of uncommon non-small cell lung cancers.

The tumour is usually found as a single large mass in the outer part of the lung. Many people have no symptoms when it is discovered; others develop a cough, chest pain, breathlessness or coughing up blood. In a classic series of 52 patients, the age of onset peaked in the fourth decade of life, and men and women were affected in similar numbers (Koss, Hochholzer and O’Leary, 1991).

Recent research has shown that most pulmonary blastomas carry acquired DICER1 mutations in the tumour, often together with changes in the beta-catenin (CTNNB1) gene (Alirezaie et al., 2024). Surgery is the main treatment, sometimes with chemotherapy and radiotherapy.

1. Key facts at a glance

Feature Details
Type of cancer Biphasic lung cancer with embryonal-looking glands and immature stroma
Group Sarcomatoid carcinoma, a rare type of non-small cell lung cancer
How common Very rare; well under 1% of lung cancers
Typical age Adults, with a wide range; often 30s to 60s
Sex Men and women affected in similar numbers
Key gene changes Acquired DICER1 and CTNNB1 (beta-catenin) mutations
Main treatment Surgical removal, sometimes with chemotherapy and radiotherapy
Outlook Variable; about 6 in 10 alive at 5 years in a US registry
Tumour Description Notes
Biphasic pulmonary blastoma Malignant fetal-type glands plus immature stroma The true “pulmonary blastoma” in current classifications
Well-differentiated fetal adenocarcinoma Fetal-type glands only, without malignant stroma Previously grouped with blastoma; now a type of adenocarcinoma with a better outlook
Pleuropulmonary blastoma A childhood tumour, often cystic Linked with inherited DICER1 variants; a separate disease

In the series by Koss and colleagues, deaths from the disease were much less frequent with the gland-only type than with the biphasic type (Koss, Hochholzer and O’Leary, 1991).

How it compares with common lung cancers

Feature Pulmonary blastoma Common non-small cell lung cancer
Typical age Often younger adults Usually over 65
Tissue Glands plus immature stroma Glands (adenocarcinoma) or squamous cells
Position Often a large peripheral mass Anywhere in the lung
Key genes DICER1, CTNNB1, TP53 EGFR, KRAS, ALK, TP53 and others
Targeted drugs None established Available for many tumours

3. Causes and risk factors

The cause is not known.

Factor Notes
Smoking Many adults with pulmonary blastoma have a history of smoking
Acquired DICER1 mutations Found in the tumour cells of most cases; usually not inherited
Beta-catenin (CTNNB1) mutations Common, especially in tumours with small nodular cell clusters called morules
TP53 mutations Seen in about half of tumours in one study

Gene studies found somatic DICER1 changes in nearly all pulmonary blastomas examined, and their DNA methylation pattern resembled that of other DICER1-related tumours rather than ordinary lung cancers (Alirezaie et al., 2024). Because a small number of people with any DICER1-related tumour carry an inherited variant, genetic counselling may be offered, particularly to younger patients.

Understanding DICER1 and beta-catenin

Gene Normal role What goes wrong
DICER1 Makes small RNA molecules that switch other genes on and off during development Mutations distort these signals, keeping cells in an immature, embryo-like state
CTNNB1 (beta-catenin) Part of the Wnt signalling pathway, which controls cell growth and how cells stick together Mutations let beta-catenin build up in the nucleus and drive growth; linked to morules
TP53 A “guardian” gene that stops damaged cells from dividing Loss allows abnormal cells to survive and multiply

These findings explain why pulmonary blastoma looks like fetal lung tissue. They may also point to future targeted treatments.

Inherited DICER1 syndrome

DICER1 tumour predisposition syndrome is an inherited condition that raises the risk of pleuropulmonary blastoma in children, certain thyroid and ovarian tumours, and other rare cancers. In adult pulmonary blastoma the DICER1 changes are usually found only in the tumour. Even so, a specialist may suggest a blood test, especially if you are young or have a personal or family history of related tumours.

4. How does it look

On chest X-ray and CT

Feature Description
Number Usually a single mass
Position Often in the outer (peripheral) lung; no favoured lobe
Size Often large, sometimes over 10 cm
Edge Usually well defined
Inside May contain areas of dead tissue or bleeding
Fluid A pleural effusion may be present with larger tumours

Under the microscope

Feature Description
Glands Tubules lined by glycogen-rich cells resembling the fetal lung
Morules Small solid nests of cells within the glands
Stroma Immature, densely cellular, primitive-looking tissue
Other elements Occasionally cartilage, muscle or bone-like areas
Stains Epithelium positive for keratin and TTF-1; stroma positive for vimentin; abnormal nuclear beta-catenin

The abnormal beta-catenin staining pattern, linked with the presence of morules, helps confirm the diagnosis (Sekine et al., 2003).

5. Symptoms

Common symptoms

  • Cough that does not go away
  • Chest pain
  • Coughing up blood (haemoptysis)
  • Breathlessness

Up to four in ten people have no symptoms, and the tumour is found on a chest X-ray done for another reason (Koss, Hochholzer and O’Leary, 1991).

Less common symptoms

Symptom What it may mean
Fever or chest infection Blockage of an airway
Weight loss and tiredness Advanced disease
Fluid around the lung Pleural spread
Bone pain or headaches Rarely, spread to bones or brain
Bleeding into the chest Rare complication of a large tumour

When to seek medical advice

See a doctor if you have a cough lasting more than three weeks, coughing up blood, chest pain or unexplained breathlessness, whatever your age.

6. Diagnosis

Test Purpose
Chest X-ray Often the first test
CT of the chest and abdomen Shows size, position and spread
PET-CT Looks for spread elsewhere
CT-guided needle biopsy Samples a peripheral mass
Bronchoscopy For central tumours or airway blockage
MRI of the brain For staging in selected cases
Lung function tests Check fitness for surgery
Molecular testing DICER1 and CTNNB1; standard lung cancer markers are also often checked

A small needle biopsy may show only one of the two components, so the full diagnosis is often made after the tumour is removed.

Why the diagnosis can be difficult

Pulmonary blastoma is so rare that most pathologists see only a few cases in their career. A needle biopsy may contain only glands, which can look like adenocarcinoma, or only stroma, which can look like a sarcoma. A review by a specialist thoracic pathologist, special stains and molecular tests help to reach the right diagnosis.

Staging

Pulmonary blastoma is staged using the TNM system for lung cancer.

Stage General meaning
Stage I-II Confined to the lung, with or without nearby lymph nodes
Stage III Spread to lymph nodes in the centre of the chest or nearby structures
Stage IV Spread to the other lung, pleura or distant organs

7. Treatment

Surgery

Complete surgical removal is the most effective treatment. In a US population study, people who did not have surgery had a higher risk of death (Bu et al., 2020).

Operation Description
Lobectomy Removal of the affected lobe; the usual operation
Pneumonectomy Removal of the whole lung for central or very large tumours
Lymph node dissection Removes and checks chest lymph nodes
Minimally invasive (keyhole) surgery Possible for some tumours

Chemotherapy

Situation Approach
After surgery Platinum-based chemotherapy is often considered, especially for larger or node-positive tumours
Before surgery Sometimes used to shrink a large tumour
Advanced disease Cisplatin or carboplatin combinations, for example with etoposide or ifosfamide

Evidence comes mainly from case reports and small series, so treatment is tailored to each person.

Radiotherapy

Radiotherapy may be used after surgery with involved margins, for tumours that cannot be removed, or to relieve symptoms from spread to the bones or brain.

Newer treatments

Immunotherapy has been tried in some sarcomatoid lung cancers. For pulmonary blastoma specifically, there is little data. Clinical trials should be considered.

Side effects

Treatment Possible side effects
Lung surgery Pain, breathlessness, air leak, chest infection
Chemotherapy Tiredness, nausea, hair loss, infection risk, kidney and hearing effects with cisplatin
Radiotherapy Tiredness, sore throat or swallowing, cough, skin changes

What treatment involves day to day

Stage What to expect
Before surgery Breathing tests, heart checks and advice to stop smoking
Hospital stay Usually 3-7 days after a lobectomy
Recovery 6-12 weeks to regain energy; breathing exercises and walking help
Chemotherapy Usually 4 cycles, each lasting 3 weeks

8. Outlook (prognosis)

Measure Reported result
Median survival in a US registry About 9 years (Bu et al., 2020)
5-year survival About 58%
10-year survival About 49%
Deaths from biphasic tumours in a classic series About half (Koss, Hochholzer and O’Leary, 1991)
Factor Effect on outlook
Complete surgical removal Better survival
Older age Higher risk of death
Spread beyond the lung Poorer outlook
Tumour 5 cm or larger Poorer outlook for biphasic tumours
Recurrence after treatment The strongest sign of poor prognosis in biphasic tumours
Biphasic rather than gland-only type Poorer outlook

9. Follow-up

Follow-up Purpose
CT scan every 3-6 months for the first 2 years Looks for recurrence
Then every 6-12 months up to 5 years Continued monitoring
Lung function and breathing review After surgery
Symptom checks New cough, pain, headaches or bone pain
Genetic counselling If an inherited DICER1 variant is suspected

10. Living with pulmonary blastoma

  • Stop smoking, which helps recovery and lowers the risk of other cancers
  • Do breathing exercises and keep walking to rebuild lung capacity
  • Join pulmonary rehabilitation if breathlessness persists
  • Have flu and pneumonia vaccinations as advised
  • Report new symptoms promptly between scans
  • Seek support from lung cancer charities and rare cancer networks

11. Frequently asked questions

Question Answer
Is it the same as pleuropulmonary blastoma? No; that is a childhood tumour with different genetics and treatment
Is it a type of lung cancer? Yes, a rare sarcomatoid non-small cell lung cancer
Is it inherited? Usually not; DICER1 changes are usually acquired in the tumour
Can it be cured? Yes, especially when completely removed at an early stage
Will I need chemotherapy? Often, depending on the stage and how completely the tumour was removed
Are targeted drugs available? Not yet specifically; research into DICER1 and beta-catenin pathways is ongoing
Why does it affect younger people? The reason is unclear, but it often occurs earlier than ordinary lung cancer
Will I be able to breathe normally after surgery? Most people adapt well after a lobectomy, though strenuous exercise may feel harder

12. Questions to ask your care team

  • Is my tumour biphasic pulmonary blastoma or fetal adenocarcinoma?
  • What is the stage, and can it be completely removed?
  • Do I need chemotherapy or radiotherapy after surgery?
  • Should I have DICER1 testing or genetic counselling?
  • Are there clinical trials for rare lung cancers I could join?
  • How often will I have CT scans?
  • Has my biopsy been reviewed by a specialist lung pathologist?

Resources

  1. Alirezaie, N. et al. (2024) ‘Exomic and epigenomic analysis of pulmonary blastoma’, Lung Cancer, 195, 107916.
  2. Bu, X. et al. (2020) ‘Epidemiological features and survival outcomes in patients with malignant pulmonary blastoma: a US population-based analysis’, BMC Cancer, 20(1), 811.
  3. Koss, M.N., Hochholzer, L. and O’Leary, T. (1991) ‘Pulmonary blastomas’, Cancer, 67(9), pp. 2368-2381.
  4. Sekine, S. et al. (2003) ‘Beta-catenin mutations in pulmonary blastomas: association with morule formation’, Journal of Pathology, 200(2), pp. 214-221.
  5. National Cancer Institute (2026) Non-Small Cell Lung Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/lung/hp/non-small-cell-lung-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.